Adverum Biotechnologies, INC Schedule 13G passive stakes

Frazier Life Sciences and related entities have reported a complete divestment of their beneficial ownership in Adverum Biotechnologies, Inc., now holding 0.0% of common stock.

Frazier Life Sciences funds updated their beneficial ownership in Adverum Biotechnologies, Inc., with Frazier Life Sciences Public Fund, L.P. holding 19.4%.

Frazier Life Sciences entities filed an amended Schedule 13G, detailing their beneficial ownership and warrant holdings in Adverum Biotechnologies, Inc.

Franklin Resources, Inc. and its principals report zero beneficial ownership in Adverum Biotechnologies, Inc., signaling a complete divestment.

BlackRock, Inc. has disclosed a 2.0% passive beneficial ownership stake in Adverum Biotechnologies, Inc., holding 414,485 shares of common stock as of June 30, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have jointly disclosed a passive beneficial ownership of 8.9% in Adverum Biotechnologies, Inc., totaling 1,871,482 shares.

BML Investment Partners, L.P. and Leonard Braden Michael have disclosed beneficial ownership of 13.8% of Adverum Biotechnologies, Inc.'s common stock, totaling 2,882,317 shares, as of March 31, 2025.

A group of investment entities and individuals associated with Venrock Healthcare Capital Partners has reported a complete divestment of their beneficial ownership in Adverum Biotechnologies, Inc. as of December 31, 2024.

BML Investment Partners, L.P. and Leonard Braden Michael have disclosed beneficial ownership of 11.4% of Adverum Biotechnologies, Inc.'s common stock as of December 31, 2024.